MedTrace Logo

Long-term Immunogenicity of L-HAV Vaccine Among Healthy Thai Children and Adolescents

NCT07032610 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2026-05-22

No results posted yet for this study

Summary

Hepatitis A virus (HAV) remains a common infection among Thai children. Two types of HAV vaccines are available in Thailand: an inactivated vaccine (I-HAV, administered in two doses 6 months apart) and a live-attenuated vaccine (L-HAV, administered as a single dose). However, neither vaccine is currently included in Thailand's Expanded Programme on Immunization (EPI). In 2024, a randomized, active-controlled, open-label, non-inferiority trial was conducted to compare the immunogenicity and safety of the two-dose I-HAV with the single-dose L-HAV in healthy Thai children and adolescents aged 18 months to 18 years. This study aims to evaluate the long-term seropositive rate and immunogenicity of anti-HAV antibodies in this population following a single dose of L-HAV.

Conditions

  • Hepatitis A
  • Hepatitis A Virus
  • Vaccine-Preventable Diseases

Sponsors & Collaborators

  • Faculty of Medicine, Chiang Mai University

    collaborator UNKNOWN

  • Chiang Mai University

    lead OTHER

Principal Investigators

  • Tavitiya Sudjaritruk, MD, PhD · Department of Pediatrics, Faculty of Medicine, Chiang Mai University

  • Natchaya Kunanitthaworn, MD · Department of Pediatrics, Faculty of Medicine, Chiang Mai University

Eligibility

Min Age
18 Months
Max Age
20 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-06-26
Primary Completion
2025-06-28
Completion
2026-07-31

Countries

  • Thailand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07032610 on ClinicalTrials.gov